Recerca

Etiopatogènia i tractament dels trastorns mentals greus (MERITT)

Buscador de publicacions

Publicacions

  • Farreny A, Aguado J, Corbera S, Ochoa S, Huerta-Ramos ME and Usall J.

    Baseline Predictors for Success Following Strategy-Based Cognitive Remediation Group Training in Schizophrenia

    JOURNAL OF NERVOUS AND MENTAL DISEASE . 204(8): 585-589. Nº de cites: 15

    [doi:10.1097/NMD.0000000000000509]

  • Huerta-Ramos ME, Escobar-Villegas MS, Rubinstein K, Unoka ZS, Grasa E, Hospedales M, Jääskeläinen E, Rubio E, Caspi A, Bitter I, Berdun J, Seppälä J, Ochoa S, Fazekas K, M-RESIST Group, Corripio I and Usall J.

    Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study

    JMIR mHealth and uHealth . 4(3): . Nº de cites: 17

    [doi:10.2196/mhealth.5716]

  • Farreny A, Del Rey-Mejías, Á., Escartin, G., Usall J, Tous, N., Haro JM and Ochoa S.

    Study of positive and negative feedback sensitivity in psychosis using the Wisconsin Card Sorting Test.

    COMPREHENSIVE PSYCHIATRY . 68: 119-128. Nº de cites: 15

    [doi:10.1016/j.comppsych.2016.04.011]

  • Vila R, Martínez-Zambrano F, Arenas O, Casas E, García-Morales E, Villellas R, Martín JR, Pérez-Franco MB, Valduciel T, Casellas D, García-Franco M, Miguel J, Balsera J, Pascual G, Julia E and Ochoa S.

    Effectiveness of an intervention for reducing social stigma towards mental illness in adolescents.

    World Journal of Psychiatry . 6(2): 239-247. Nº de cites: 14

    [doi:10.5498/wjp.v6.i2.239]

  • Cunill R and Castells X.

    The treatment of dual ADHD: a drop in the ocean.

    Adicciones . 28(3): 131-135. Nº de cites: 1

    [doi:10.20882/adicciones.836]

  • Fusté M, Meléndez-Pérez I, Villalta-Gil V, Pinacho R, Villalmanzo N, Cardoner N, Menchón JM, Haro JM, Soriano-Mas C and Ramos B.

    Specificity proteins 1 and 4, hippocampal volume and first-episode psychosis.

    BRITISH JOURNAL OF PSYCHIATRY . 208(6): 591-592. Nº de cites: 2

    [doi:10.1192/bjp.bp.114.152140]

  • Martínez-Zambrano F, Pizzimenti M, Barbeito S, Vila R, Comellas G, Escandell MJ, Hernández MJ, Fernández-de Corres B, González-Pinto A, López-Peña MP, Martínez M, Puig M, Quilis J, Vega P and Ochoa S.

    Spanish version of the Link's Perceived Devaluation and Discrimination scale.

    Psicothema . 28(2): 201-206. Nº de cites: 6

    [doi:10.7334/psicothema2015.89]

  • Usall J, Huerta-Ramos ME, Labad J, Cobo J, Nuñez C, Creus M, Parés GG, Cuadras-Palleja D, Franco J, Miquel E, Reyes JC, Roca M and RALOPSYCAT Group.

    Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial

    SCHIZOPHRENIA BULLETIN . 42(2): 309-317. Nº de cites: 48

    [doi:10.1093/schbul/sbv149]

  • Garriga M, Pacchiarotti I, Kasper S, Zeller SL, Allen MH, Vázquez G, Baldaçara L, San L, McAllister-Williams RH, Fountoulakis KN, Courtet P, Naber D, Chan EW, Fagiolini A, Möller HJ, Grunze H, Llorca PM, Jaffe RL, Yatham LN, Hidalgo-Mazzei D, Passamar M, Messer T, Bernardo M and Vieta E.

    Assessment and management of agitation in psychiatry: Expert consensus.

    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY . 17(2): 86-128. Nº de cites: 160

    [doi:10.3109/15622975.2015.1132007]

  • Cuevas-Esteban J, Campayo A, Haro JM, Guerreo A and Lobo A.

    Parkinsonismo, depresión y demencia: una tríada asoladora que debe investigarse

    Psicogeriatría . 6(2): 39-49.